| Literature DB >> 35885572 |
Daniela Iacob1, Ileana Enatescu1, Mirabela Dima1, Elena Bernad2, Manuela Pantea1, Daiana Bozgan3, Sandor Bernad4, Marius Craina2.
Abstract
The Coronavirus disease 2019 (COVID-19) pandemic has exposed the vulnerable neonatal population to unknown risks. Given that herd immunity is has not been reached, the entire population is susceptible to Severe Acute Respiratory Syndrome Coronavirus 2 Virus(SARS-CoV-2) infection. The arising concern about the vertical transmission of neonatal complications caused by the novel coronavirus is a continuous challenge for managing newborns, considering the rare cases and unclear guidelines. Therefore, a retrospective study was conducted in a tertiary unit from Timisoara, Romania. Of the 283 newborns born during the study period, only 3 neonates were diagnosed with SARS-CoV-2 infection in the first 24 h of life (DOL-0). The present study plans to identify the findings, including clinical features, laboratory characteristics, and outcomes of newborns with vertical transmission of SARS-CoV-2. All infected neonates were confirmed with COVID-19 by Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) from nasal aspirates and were isolated in the neonatology department. They were the first and the only neonate infected at birth from the West part of Romania. The clinical findings were unremarkable except for one neonate who developed mild respiratory distress syndrome. Elevated IgG-specific anti-SARS-CoV-2 serum levels were found in one newborn. Swab samples in DOL-0 strengthened the awareness of vertical transmission, although peripartum SARS-CoV-2 infection does not seem responsible for severe symptoms. We conclude that vertical transmission is rare in late pregnancy. Even if the studied newborns showed mild forms of COVID-19, it is essential to note that newborns represent a particular category of patients. More studies are needed to complete the observations of this study.Entities:
Keywords: COVID-19; SARS-CoV-2 infection; late pregnancy; neonates; vertical transmission
Year: 2022 PMID: 35885572 PMCID: PMC9324313 DOI: 10.3390/diagnostics12071668
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Characteristics of the newborns.
| Parameters | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
|
| |||
| Place of birth | CEHPBT | CEHPBT | Secondary maternity |
| Gestational age (weeks) | 38 | 39 | 39 |
| Type of birth | Vaginal | C-section | C-section |
| Presentation at birth | Cephalic | Cephalic | Cephalic |
| Gender | male | male | male |
| Weight at birth (g) | 2990 | 3270 | 2900 |
| Length at birth (cm) | 50 | 52 | 50 |
| Head circumference (cm) | 33 | 34 | 31 |
| Chest circumference (cm) | 33 | 34 | 32 |
| Ponderal index (2PI) | 2.39 | 2.32 | 2.32 |
| Classification based on PI | AGA | AGA | AGA |
|
| |||
| Appearance | General cyanosis | Acrocyanosis | Acrocyanosis |
| Pulse | >100 | >100 | >100 |
| Grimace | PRS | PRS | PRS |
| Activity | Active | Active | Active |
| Respiration | Vigorous cry | Vigorous cry | Vigorous cry |
| At 1 min | 8 | 9 | 9 |
| At 5 min | 10 | 10 | 10 |
C-section—cesarean section; PI—ponderal index was calculated fetal weights (in grams) × 100/fetal length (in centimeters); AGA—appropriate for gestational age; PRS = prompt response to stimulation.
Clinical findings.
| Parameters | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
|
| mild | none | none |
|
| |||
| DOL—1 | moderate | none | none |
| DOL—2 | moderate | mild | mild |
| DOL—3, 4 | moderate | mild | moderate |
| DOL—5, 6 | intense | mild | moderate |
| DOL—7 | moderate | in regression | in regression |
|
| |||
| DOL—1, 2 | no | no | no |
| DOL—3–5 | yes | yes | yes |
| DOL—6 | yes | no | yes |
| DOL—7 | yes | discharged | discharged |
|
| |||
| DOL—1–3 | no | no | no |
| DOL—4–7 | yes | no | no |
RDS—respiratory distress syndrome; jaundice—mild = total bilirubin <8.8 mg/dL; moderate = total bilirubin between 8.8–14.7 mg/dL; severe = total bilirubin > 14.7 mg/dL.
Laboratory tests during hospitalization.
| Parameters | Patient 1 | Patient 2 | Patient 3 | Reference Range | ||||
|---|---|---|---|---|---|---|---|---|
| DOL-1 | DOL-3 | DOL-5 | DOL-1 | DOL-2 | DOL-3 | DOL-2 | Age 0–month | |
| Leukocytes | 11.2 | 8.18 | 9.00 | 20.52 | 12.38 | NA | 12.76 | 9–30 × 103/μL |
| Granulocytes | 6.3 | 4.19 | 1.21 | 13.87 | 8.50 | NA | 7.78 | 1–20 × 103/μL |
| Lymphocytes | 4.3 | 1.94 | 5.47 | 5.11 | 2.60 | NA | 2.95 | 2–11 × 103/μL |
| Hemoglobin | 18.1 | 16.8 | 17.5 | 16.5 | 16.8 | NA | 19.2 | 13.4–19.9 g/dL |
| Hematocrit | 51.9 | 46.1 | 48.6 | 47.9 | 47.7 | NA | 52.5 | 42–65% |
| Thrombocytes | 253.000 | 172.000 | 178.000 | 183.000 | 180.000 | NA | 246.000 | 242.000–378.000/μL |
| 1 CRP | 7.4 | 0.99 | <5 | 32.36 | NA | 10.35 | <0.5 | <0.5 mg/dL |
| 2 ALT | 33 | NA | 38 | 24 | NA | NA | 12 | 0–35 U/L |
| 3 AST | 86 | NA | 69 | 50 | NA | NA | 73 | 14–36 U/L |
| 4 CK | NA | NA | NA | 305 | NA | NA | 942 | 65–580 U/L |
| 5 TB | 6.2 | 11.2 | 13.6 | - | NA | NA | 8.55 | <6.0 mg/dL |
| 6 LDH | NA | NA | NA | 668 | NA | NA | 735 | 160–450 U/L |
| Ferritin | NA | 359 | 627 | 216 | NA | NA | 92 | 25–200 μg/L |
| IgG anti SpikeS1 quantitative | NA | NA | <2 | <2 | NA | NA | 187 | <17.8 7 BAU = NEGATIVE;>17.8 BAU = POSITIVE |
| Anti-SARS-CoV-2 TOTAL (IgA IgM IgG) | NA | NA | 0.05 | 0.09 | NA | NA | NA | 0.00–0.99 8 s/co = UNEREACTIVE;≥1.00 REACTIVE |
1 CRP = C-reactive protein; 2 ALT = alanine aminotransferase; 3 AST = aspartate aminotransferase; 4 CK = creatin phosphokinase; 5 TB = total bilirubin; 6 LDH = lactate dehydrogenase; 7 BAU = binding antibody units; 8 s/co = signal/cut-off.
Figure 1Recommendations at discharge.